Synageva gains orphan-drug status for enzyme-replacement therapy

07/7/2010 | Boston Globe (tiered subscription model), The

The FDA granted orphan-drug designation to SBC-102, Synageva BioPharma's enzyme-replacement therapy. The drug candidate is being developed as a treatment for lysosomal acid lipase deficiency, a rare disorder for which there is no approved treatment.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA